EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 340 filers reported holding EXELIXIS INC in Q2 2021. The put-call ratio across all filers is 1.12 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,568,004 | +335.8% | 987,094 | +281.1% | 0.25% | +328.8% |
| Q2 2023 | $4,949,490 | -63.7% | 259,000 | -57.0% | 0.06% | -73.3% |
| Q1 2022 | $13,643,000 | +24.0% | 601,800 | 0.0% | 0.22% | +39.9% |
| Q4 2021 | $11,001,000 | -13.5% | 601,800 | 0.0% | 0.16% | -24.0% |
| Q3 2021 | $12,722,000 | +16.0% | 601,800 | 0.0% | 0.21% | +2.0% |
| Q2 2021 | $10,965,000 | -18.9% | 601,800 | +0.6% | 0.20% | -32.0% |
| Q1 2021 | $13,516,000 | +146.9% | 598,308 | +119.3% | 0.30% | +106.9% |
| Q4 2020 | $5,475,000 | -82.9% | 272,800 | -79.2% | 0.14% | -86.2% |
| Q3 2020 | $32,076,000 | – | 1,311,887 | – | 1.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |